Migraine – Global Clinical Trials Review, H2, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData’s clinical trial report provides an overview of the migraine clinical trials scenario. This report provides top-line data relating to the clinical trials on migraine. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report also provides prominent drugs for in-progress trials (based on the number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news, etc across the globe. Clinical trials database undergoes periodic updates by dynamic process.
The migraine clinical trial report consists of 1787 trials. Trials conducted by companies in Phase IV, Phase III, Phase II, Phase I, and Phase 0 stand at 147, 237, 213, 511, and 2 respectively. Similarly, the trials with different status compile of Completed – 1329, Ongoing – 197, Planned – 96, Suspended – 6, Terminated – 57, and withdrawn – 102. Out of 1329 completed trials 791 trials have achieved endpoint.
What are the market dynamics of the global migraine therapeutics clinical trials sector?
The number of migraine clinical trials conducted globally has increased by over 34% for the period 2016-2020. Out of 1,329 completed trials, 957 trials have results and over 83% of trials reached endpoints. As of November 2021, there were 197 clinical trials in progress and 1,329 trials were completed. The trials that were terminated/suspended or withdrawn accounted for 165. This was due to the lack of efficacy, safety, and lack of accrual of subjects. There were 197 clinical trials in progress of which more than 29% were in Phase III study.
What are the top regions and countries in the global migraine therapeutics clinical trials sector?
In total there were 1,787 clinical trials conducted on migraine, as of November 2021, of these 563 clinical trials were in North America. During the same period, the US has the highest average patient enrollment in migraine clinical trials.
North America: The US has the highest number of migraine clinical trials followed by Canada and Mexico.
Europe: Among the European countries, Germany has the highest number of migraine clinical trials followed by the UK, Denmark, Italy, and Russia.
Asia-Pacific: In the Asia-Pacific region, China has the highest number of migraine clinical trials followed by Japan, Australia, South Korea, and India.
Middle East and Africa: Iran has the highest number of migraine clinical trials followed by Israel and South Africa.
South and Central America: Brazil has the highest number of migraine clinical trials followed by Chile, Colombia, EI Salvador, and Argentina.
G7 countries: Among the G7 (The US, the UK, Germany, France, Italy, Canada, and Japan) countries, Italy has the highest proportion of migraine to central nervous system clinical trials as of November 2021. In total there were 955 clinical trials conducted on Migraine, as of November 2021 in G7 Countries, of these 525 clinical trials were in the US. As of November 2021, there were 97 clinical trials in progress and 564 trials are completed. The trials that are terminated/suspended or withdrawn accounted for 66. This was due to the lack of efficacy, safety, and lack of accrual of subjects.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Russia has the highest proportion of migraine to central nervous system clinical trials as of November 2021. In total there were 356 clinical trials conducted on migraine, as of November 2021 in E7 Countries, of these 137 clinical trials were in China. As of November 2021, there were 52 clinical trials in progress and 207 trials were completed. The trials that were terminated/suspended or withdrawn accounted for 32. This was due to the lack of efficacy, safety, and lack of accrual of subjects.
Global migraine therapeutics clinical trials sector, by regions
For more regional insights, download a free report sample
Which are the key companies in the global migraine therapeutics clinical trials sector?
As of November 2021, AbbVie Inc sponsored the highest number of migraine clinical trials, followed by Eli Lilly and Co and GlaxoSmithKline Plc. Other major companies in the sector are Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Biohaven Pharmaceutical Holding Company Ltd, Dr. Reddy’s Laboratories Ltd, Banyan Group Inc, Johnson & Johnson, and Amgen Inc.
Global migraine therapeutics clinical trials sector, by key companies
To know more about key companies, download a free report sample
Market report scope
Key countries | The US, the UK, Germany, France, Italy, Canada, Japan, Brazil, Russia, India, China, Mexico, Turkey, and Indonesia |
Key companies | AbbVie Inc, Eli Lilly and Co and GlaxoSmithKline Plc, Merck & Co Inc, Tev Pharmaceutical Industries Ltd, Biohaven Pharmaceutical Holding Company Ltd, Dr. Reddy’s Laboratories Ltd, Banyan Group Inc, Johnson & Johnson, and Amgen Inc. |
Scope
- The report provides a snapshot of the global clinical trials landscape.
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and End point status.
- The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
- The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with the reason for unaccomplishment.
- The Report provides enrollment trends for the past five years.
- Report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regard to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country-level.
Eli Lilly and Co
GlaxoSmithKline Plc
Merck & Co Inc
Teva Pharmaceutical Industries Ltd
Biohaven Pharmaceutical Holding Company Ltd
Dr. Reddy's Laboratories Ltd
Banyan Group Inc
Johnson & Johnson
Amgen Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key countries in the global migraine therapeutics clinical trials sector?
Key countries in the global migraine therapeutics clinical trials sector are the US, the UK, Germany, France, Italy, Canada, Japan and Brazil, Russia, India, China, Mexico, Turkey, and Indonesia.
-
Which are the key companies in the global migraine therapeutics clinical trials sector?
Key companies in the global migraine therapeutics clinical trials sector are AbbVie Inc, Eli Lilly, and Co and GlaxoSmithKline Plc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Biohaven Pharmaceutical Holding Company Ltd, Dr. Reddy’s Laboratories Ltd, Banyan Group Inc, Johnson & Johnson, and Amgen Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.